Decoy Therapeutics Inc. (DCOY) — Cash Flow-to-Debt Ratio
Decoy Therapeutics Inc. (DCOY) has a Cash Flow-to-Debt Ratio of -0.64x as of March 2026, meaning its operating cash flow of $-2.89 Million could theoretically repay -1% of its total liabilities ($4.55 Million) in one year. Explore Decoy Therapeutics Inc. cash conversion from operations to assess how effectively this company generates cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Decoy Therapeutics Inc. Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Decoy Therapeutics Inc. across 12 annual periods. Also explore total assets of Decoy Therapeutics Inc. for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Decoy Therapeutics Inc. (2014–2025)
Year-by-year debt coverage analysis for Decoy Therapeutics Inc.. For market capitalisation and broader financial context, see DCOY company net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.93x | $-4.83 Million | $5.17 Million | ▲ +68.8% |
| 2024 | -2.99x | $-4.53 Million | $1.51 Million | ▲ +69.7% |
| 2023 | -9.89x | $-12.85 Million | $1.30 Million | ▼ -139.7% |
| 2022 | -4.12x | $-17.60 Million | $4.27 Million | ▲ +14.6% |
| 2021 | -4.83x | $-10.20 Million | $2.11 Million | ▼ -30.0% |
| 2020 | -3.72x | $-10.31 Million | $2.77 Million | ▼ -6.4% |
| 2019 | -3.49x | $-11.58 Million | $3.31 Million | ▲ +83.6% |
| 2018 | -21.32x | $-23.60 Million | $1.11 Million | ▼ -352.7% |
| 2017 | -4.71x | $-27.72 Million | $5.89 Million | ▲ +42.7% |
| 2016 | -8.22x | $-32.05 Million | $3.90 Million | ▼ -14.1% |
| 2015 | -7.21x | $-20.75 Million | $2.88 Million | ▼ -4285.6% |
| 2014 | -0.16x | $-6.93 Million | $42.15 Million | — |